Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...

MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Moderna stock slid nearly 17% on Monday, after the US biotech firm slashed its 2025 sales forecast range by $1bn. An ...

U.S. stock futures are pointing higher ahead of wholesale inflation data, China mulls selling TikTok to Elon Musk, and ...

Vaccine maker Moderna's (NASDAQ: MRNA) stock prices fell by over 16% on 13th January to close at £28.81 ($35.15) after the ...

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health ...